Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.61 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA3 | P07451 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.48 |
| ▸ | ABL1 | P00519 | 4/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.48 |
| ▸ | BCR | P11274 | 4/20 | 0.48 |
| ▸ | CA6 | P23280 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903464 | 0.88 | APP (0.75) | APPCA12CA2CA9CA3 | |
| SCHEMBL674063 | 0.88 | BACE1 (0.57) | APPCA12CA2CA9CA3 | |
| SCHEMBL14400750 | 0.88 | APP (0.74) | APPCA12CA2CA9CA3 | |
| SCHEMBL673609 | 0.88 | APP (0.74) | APPCA12CA2CA9CA3 | |
| SCHEMBL19026498 | 0.87 | APP (0.57) | APPCA12CA2CA9CA1 | |
| SCHEMBL23668457 | 0.87 | APP (0.48) | APPCA12CA2CA9CA3 | |
| SCHEMBL4267390 | 0.85 | ACHE (0.52) | APPCA12CA2CA9CA1 | |
| SCHEMBL4264799 | 0.85 | APP (0.46) | APPCA12CA2CA9CA1 | |
| SCHEMBL4277452 | 0.85 | PTGS1 (0.47) | APPCA12CA2CA9CA1 | |
| SCHEMBL4267409 | 0.84 | APP (0.60) | APPCA12CA2CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | claimed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | claimed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | claimed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | claimed |
| CN-111526873-A | Substituted tolanes for regulating microbial colonization | 生物曼迪克斯有限责任公司 | 2020-08-11 | — | — | CN | claimed |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2020-07-02 | — | — | US | claimed |
| EP-3658128-A1 | SUBSTITUTED TOLANS FOR THE MODULATION OF MICROBIAL COLONIZATION | Biomendics, LLC (US) | 2020-06-03 | — | — | EP | claimed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | claimed |
| WO-2019023425-A1 | SUBSTITUTED TOLANS FOR THE MODULATION OF MICROBIAL COLONIZATION | BioMendics, LLC (US) | 2019-01-31 | — | — | WO | claimed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | claimed |
| EP-3280402-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | Biomendics LLC (US) | 2018-02-14 | — | — | EP | claimed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | claimed |
| WO-2016164531-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | BioMendics, LLC (US) | 2016-10-13 | — | — | WO | claimed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | claimed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | claimed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | claimed |
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | APP 4010/4885CA12 4596/4885CA2 3675/4885 |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | APP 3466/4885CA12 4823/4885CA2 4202/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | APP 4260/4885CA12 4675/4885CA2 3726/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | APP 3850/4885CA12 4648/4885CA2 3785/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | APP 4010/4885CA12 4596/4885CA2 3675/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | APP 4010/4885CA12 4596/4885CA2 3675/4885 |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | APP 3466/4885CA12 4823/4885CA2 4202/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | APP 3466/4885CA12 4823/4885CA2 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.